ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Rosige Zukunft - 500 Beiträge pro Seite

[js200]

Millennium To Ship Velcade, FDA Reports On Xoliar and Other Biotechnology and Drug Industry News

Wednesday, May 14, 2003 13:11 ET

City of Industry, CA, May 14, 2003 (financialnewsusa.com via COMTEX) -- Millennium Pharmaceuticals Inc. (NasdaqNM: MLNM) will be ready to ship its just-approved multiple myeloma drug Velcade next week, Chief Financial Officer Mark Levin said. The company has a sales force hired and trained to sell the drug, which was approved by the Food and Drug Administration Tuesday evening to treat patients who have failed other treatments for the deadly blood cancer, he said on a conference call. But the company still plans to announce a partnership with a larger biotech or pharmaceutical company to help shoulder the marketing efforts sometime this quarter, a Millennium spokeswoman said.

Able Laboratories Inc. (NasdaqNM: ABRX) expanded its total credit facilities by $8.3 million. In a press release Wednesday, the company said it expanded its working capital revolving credit facility to $10 million from $5.9 million, and expanded its nonrestoring equipment financing line to $10 million from $5.8 million. The expanded credit will fund additional equipment purchases and leasehold improvements. Virtually all of the company`s assets are listed as collateral for the equipment and working capital financing lines.

Shares of Ariad Pharmaceuticals Inc. (NasdaqNM: ARIA) rose more than 52% Wednesday after the U.S. District Court in Massachusetts declined a motion from Eli Lilly & Co. to dismiss a patent-infringement suit, bringing the companies one step closer to trial. Ariad, a pharmaceutical company based in Cambridge, Mass., said late Tuesday that the court declined to dismiss a patent-infringement suit filed in June by Ariad and co-plaintiffs. The lawsuit alleges that through the sales of osteoporosis drug Evista and septic-shock drug Xigris, Lilly infringed Ariad`s patent-covering methods of treating diseases by regulating NF-(kappa)B-cell signaling activity. The co-plaintiffs are Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research, and the president and fellows of Harvard College.

Global Path Inc. (OTCBB: GBPI) recently announced the signing of a Definitive Agreement to acquire nine significant patented bioscience products from General Cosmetics Corporation (GCC), based in Munich. The nine significant bioscience discoveries include three market ready products in the pain management and arthritis market with an additional six products ready for market once branding work has been completed. All products have been patented and are cleared under Food and Drug Administration (FDA) regulations for immediate roll out in the United States. Global Path Inc. is a strategic holding company focused on acquiring, expanding and developing companies in sectors which can create the highest and best opportunities for investors. Global Path provides strategic, financial and business resources to position its portfolio companies as industry leaders. To find out more about Global Path Inc., visit our website at www.globalpathinc.com.

Patients taking the experimental asthma drug Xolair may have twice the risk of developing cancer as those not taking the medication, according to a report issued by the U.S. Food and Drug Administration on Wednesday. But the drug, being developed by Genentech Inc. (NYSE: DNA), Novartis AG (NOVZn.VX) (NYSE: NVS) and Tanox Inc. (NasdaqNM: TNOX), effectively prevented asthma symptoms from worsening among patients also taking widely used steroid-based medicines, FDA staff members concluded in a separate report. The two reports -- one on the safety of Xolair and one about its effectiveness -- were issued in preparation for an FDA panel meeting on Thursday to evaluate the drug. The reports were unveiled on the FDA`s Web site on Wednesday.

About Financial News USA

Financial News USA is a next generation financial news network that provides news coverage to OTC Bulleting Board companies through its proprietary wire service, OTCBBWire. Call or visit us today to sign up for free news alerts and to find out how Financial News USA can help enhance the awareness of your company`s news to the global financial community. Financial News USA and its affiliates may have up to a 4.9% equity position in the companies mentioned herein, please visit the disclaimer at www.financialnewsusa.com.

By Staff Reporter
CONTACT: Financial News USA
Tel: [phone]
Email: [e-mail]
Web: www.financialnewsusa.com

URL: http://www.financialnewsusa.com



(C) 2003 Financial News USA, All rights reserved.


-0-


SUBJECT CODE: Corporate Event

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


05/14/2003 (13:11 ET) Millennium To Ship Velcade, FDA Reports On Xoliar and Other Biotechnology and Drug Industry News - Financial News USA



05/14/2003 (11:28 ET) Momentum Traders Reports on ARIA - Knobias



05/14/2003 (11:20 ET) New 8-K just released for ARIA - Edgar



05/14/2003 (09:46 ET) VOLUME(+): ARIA Volume 234% > 20-adsv, Stock +69.64% - Knobias



05/14/2003 (09:40 ET) GAP(+): Opening Higher ARIA, TFSM, GNSY, ARES, EPHO - Knobias



05/14/2003 (09:34 ET) Court Rules in Favor Of ARIA in Patent Suit w/ LLY - Knobias



05/13/2003 (16:42 ET) ARIAD and Co-Plaintiffs Obtain Favorable Court Ruling in Lilly Patent Infringement Lawsuit - Business Wire



05/13/2003 (11:54 ET) New 10-Q just released for ARIA - Edgar



05/13/2003 (09:32 ET) ERN(+): ARIA/Q1 (15c) vs (19c); EPS +21% Y/Y; No Guidance - Knobias



05/13/2003 (09:21 ET) New 8-K just released for ARIA - Edgar



05/13/2003 (07:30 ET) ARIAD Reports First Quarter 2003 Results; Latest Studies Supporting Use of Product Candidate, AP23464, to Treat Advanced and Drug-Resistant Cancers Announced - Business Wire



05/09/2003 (09:35 ET) New 8-K just released for ARIA - Edgar



05/09/2003 (07:30 ET) ARIAD Licenses Its NF-kappa-B Technology to DiscoveRx, Leading Developer of High-Throughput Screening Assays - Business Wire



05/07/2003 (08:35 ET) PREMARKET: ARIA Begins Enrollment for Phase 1 Study - Knobias



05/07/2003 (08:11 ET) New 8-K just released for ARIA - Edgar



05/07/2003 (07:30 ET) ARIAD Begins Patient Enrollment in Two Clinical Studies of Its Lead Cancer Product Candidate - Business Wire



05/06/2003 (07:32 ET) ARIAD Board Member Honored as Outstanding Director at the Kellogg School of Management - Business Wire



04/25/2003 (10:31 ET) VOLUME(-): ARIA Volume 19% > 20-adsv, Stock -4.58% - Knobias



04/24/2003 (10:07 ET) VOLUME(+): ARIA Volume 24% > 20-adsv, Stock +14.10% - Knobias



04/23/2003 (14:21 ET) VOLUME(-): ARIA Volume 53% > 20-adsv, Stock -0.96% - Knobias



company profile

Discovers and develops breakthrough medicines that regulate cell signaling with small molecules. It is developing a comprehensive approach to the treatment of cancer and is focused on a series of product candidates for targeted oncology indications. ... MORE INFO

CONTACT: Harvey J. Berger, M.D. (CEO)

JS200

[js200]

http://www.investtech.com/nasdaq/ana/aria.htm

JS200